Study S002529

The Impact of Multivitamin Supplementation on Micronutrient Levels in GLP-1 Users: A Randomized, Double-Blind, Placebo-Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07234916
Acronym: VITAGLP
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: ENROLLING_BY_INVITATION
Enrollment: 246
Start: 2025-12-16
Primary completion: 2027-03-16
Lead sponsor: Erasmus Medical Center
Conditions: Weight Loss; Nutritional Deficiencies; GLP - 1; Obese Patients
Interventions: DIETARY_SUPPLEMENT:Multivitamin Supplementation; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:ABR 2025 GLP

Registered primary outcomes

serum levels [15 months]

Linked records (9)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006476	Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Moiz A, The American journal of medicine	2025	Narrative review	PMID 39892489 DOI	registry reference RESULT:39892489
R0007492	Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. Bettadapura S, International journal of obesity (2005)	2025	Narrative review	PMID 38454010 DOI	registry reference RESULT:38454010
R0011152	Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Mechanick JI, Obesity reviews : an official journal of the International Association for the Study of Obesity	2025	Other trial	PMID 39295512 DOI	registry reference RESULT:39295512
R0001338	Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. He L, Frontiers in pharmacology	2024	Nonrandomized study	PMID 39040467 DOI	registry reference RESULT:39040467
R0006212	Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Christensen S, Obesity pillars	2024	Narrative review	PMID 39175746 DOI	registry reference RESULT:39175746
R0009445	Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist. Gentinetta S, Diabetes, metabolic syndrome and obesity : targets and therapy	2024	Commentary	PMID 39722834 DOI	registry reference RESULT:39722834
R0004491	Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Liu L, Frontiers in endocrinology	2022	Nonrandomized study	PMID 36568085 DOI	registry reference RESULT:36568085
R0023297	The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Friedrichsen M, Diabetes, obesity & metabolism	2021	Randomized trial	PMID 33269530 DOI	registry reference RESULT:33269530
R0008567	A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Sargeant JA, Endocrinology and metabolism (Seoul, Korea)	2019	Narrative review	PMID 31565876 DOI	registry reference RESULT:31565876